Dr. Nero Oligist's Landmark Study:Disproving a Causal Link Between Iron and Neurodegeneration in Multiple SclerosisDr. Nero Oligist, I. M. Starvin Grad, Dr. Varr Mints
A review of the growing literature concerning CCSVI is indicating some connection to venous reflux which leads to iron deposition and lesion formation in the brain and spinal cord. Recent development of MRI enabled to determine brain iron levels in a quantitative manner, which has put more interest on studying the role of iron in MS. Evidence for abnormal iron homeostasis in MS also comes from analysis of iron and iron-related proteins in CSF and blood and postmortem MS brain sections.
However, these investigative processes are necessarily slow and expensive in generating data. Dr. Nero Oligist has pioneered an entirely different approach in iron reflux and deposition studies. He has engineered a novel, low cost, method of directly applying an iron source to EAE laboratory mice to study absorption rates and subsequent lesion formation.
"My device directly and nearly instantaneously, places an iron load challenge typically at the C5-C6 cervical level on the subject EAE mice," writes Dr. Nero Oligist in his paper. "This technique also simultaneously prepares the subject for postmortem dissection of brain and nerve tissues," he states. The paper abstract notes that 101 test mouse subjects were examined and there wasn't a single observed example of brain lesions of the type definitive of MS pathology. In response to peer reviews, that the iron contact times were too brief, Dr. Nero Oligist allowed the treated mice to "ripen" for 24 hours before removing them from his device. There was no additional measurable uptake of iron in the EAE mice subjects, although the odor emitting from them increased at an exponential rate.
"The study reaches the inescapable conclusion that iron plays no role in MS," determined Dr. Nero Oligist.
However, the paper did observe a difficulty in the initial design of the iron disposition device study. Test mice were reluctant to participate in the study, and shunned the device. This problem was overcome by the placement of the a food attractant in the device, and then the EAE mice subsequently voluntarily joined in the study.
The corporate sponsor of the study, Nostrum Remedium, Inc., places great marketing weight to the results of Dr. Nero Oligist's work on iron. The CEO for Nostrum Remedium, Inc., O. Bese Katt, stated that: "This study again points to the only effective treatment option for MS is our patented line of Placebo prescription drugs."
"We have recently added a bitter tasting Placebo drug, to our existing sugar pill drug, because some patients will only accept something as a drug if it is unpleasant tasting." Recent product development has resulted in significant cost savings in their sugar pill line. "We have successfully substituted GMO corn syrup instead of traditional cane sugar in our pills; and are reaping major cost savings," noted O. Bese Katt.
"These savings will enable Nostrum Remedium, Inc., to fully fund our executive compensation bonuses,"
O. Bese Katt gleefully noted.